July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
CRISPR/Cas9 Targeted Disruption of Herpes Simplex Virus type 1 in a Rabbit Latency Model Reduces Viral Reactivation and Associated Corneal Pathology
Author Affiliations & Notes
  • Christopher M Owens
    Virology, Editas Medicine, Cambridge, Massachusetts, United States
  • Benjamin Diner
    Virology, Editas Medicine, Cambridge, Massachusetts, United States
  • Robert Fusco
    Virology, Editas Medicine, Cambridge, Massachusetts, United States
  • Emily King
    Virology, Editas Medicine, Cambridge, Massachusetts, United States
  • Ari Friedland
    Platform, Editas Medicine, Cambridge, Massachusetts, United States
  • Pankhuri Singhal
    Platform, Editas Medicine, Cambridge, Massachusetts, United States
  • Kiran Gogi
    Platform, Editas Medicine, Cambridge, Massachusetts, United States
  • Fred Harbinski
    Platform, Editas Medicine, Cambridge, Massachusetts, United States
  • Shen Shen
    Pharmacology, Editas Medicine, Cambridge, Massachusetts, United States
  • Michael Stefanidakis
    Pharmacology, Editas Medicine, Cambridge, Massachusetts, United States
  • Luis Barrera
    Platform, Editas Medicine, Cambridge, Massachusetts, United States
  • David Bumcrot
    Pipeline, Editas Medicine, Cambridge, Massachusetts, United States
  • Donna Neumann
    Pharmacology & Experimental Therapeutics, LSUHSC-New Orleans, New Orleans, Louisiana, United States
  • Charlie Albright
    Pipeline, Editas Medicine, Cambridge, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Christopher Owens, Editas Medicine (E), Editas Medicine (F); Benjamin Diner, Editas Medicine (E), Editas Medicine (F); Robert Fusco, Editas Medicine (E), Editas Medicine (F); Emily King, Editas Medicine (F); Ari Friedland, Editas Medicine (E), Editas Medicine (F); Pankhuri Singhal, Editas Medicine (E), Editas Medicine (F); Kiran Gogi, Editas Medicine (E), Editas Medicine (F); Fred Harbinski, Editas Medicine (E), Editas Medicine (F); Shen Shen, Editas Medicine (E), Editas Medicine (F); Michael Stefanidakis, Editas Medicine (E), Editas Medicine (F); Luis Barrera, Editas Medicine (E), Editas Medicine (F); David Bumcrot, Editas Medicine (E), Editas Medicine (F); Donna Neumann, Editas Medicine (C); Charlie Albright, Editas Medicine (E), Editas Medicine (F)
  • Footnotes
    Support  NIH Grant 1R43AI120302-01
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 374. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christopher M Owens, Benjamin Diner, Robert Fusco, Emily King, Ari Friedland, Pankhuri Singhal, Kiran Gogi, Fred Harbinski, Shen Shen, Michael Stefanidakis, Luis Barrera, David Bumcrot, Donna Neumann, Charlie Albright; CRISPR/Cas9 Targeted Disruption of Herpes Simplex Virus type 1 in a Rabbit Latency Model Reduces Viral Reactivation and Associated Corneal Pathology. Invest. Ophthalmol. Vis. Sci. 2018;59(9):374. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Recurrent herpes simplex virus (HSV) ocular keratitis, a result of latent virus reactivation within the trigeminal ganglia (TG), is considered the leading cause of infectious corneal blindness worldwide. Current standard of care fails to block latent virus reactivation and, for many patients, is contraindicated. To address this unmet medical need, we have developed a gene editing approach using CRISPR-associated protein-9 (Cas9) nuclease and guide RNAs (gRNAs) to target latent HSV-1 genomes in a rabbit model of recurrent HSV-1 keratitis.

Methods : gRNAs (N=411) assembled into ribonucleoproteins were screened against HSV-1-specific sequences in high throughput in vitro assays. For the rabbit model of recurrent HSV-1 keratitis, HSV-1 strain 17Syn+ was applied topically to scarified corneas of New Zealand white rabbits and allowed to establish latency in the TG over four weeks. Rabbits were then treated with adeno-associated virus (AAV) serotype 8 vectors expressing Cas9 and gRNAs targeting GFP (negative control) or HSV-1 genes, applied individually or in combinations, to re-scarified corneas at a total of 1.0E+11 viral genomes/eye. Latent HSV-1 was reactivated in each rabbit using epinephrine iontophoresis. Post-reactivation, tear swabs were collected daily and slit lamp examinations were conducted every 2-3 days. HSV-1 virions were detected in tear films using a plaque assay. Viral genomes in TG were quantified using qPCR. Statistical analyses utilized one-way ANOVA.

Results : Of the 411 gRNAs screened, 56 hits targeting 13 essential viral genes were selected for follow up. In rabbits, gRNAs targeting UL48 or RL2 inhibited HSV-1 production in tear films up to 64% (p>0.05) and corneal lesions were suppressed by up to 56% (p>0.05); a combination of gRNAs targeting UL48 and RL2 inhibited HSV-1 virions in tear films by 75% (p=0.03) and reduced corneal lesions by 91% (p<0.01), compared to the control group.

Conclusions : This study is the first to establish an in vivo proof of concept for a topically applied AAV expressing CRISPR/Cas9 editing machinery for controlling recurrent HSV ocular keratitis. Efficacy was greatest using combinations of gRNAs to reduce secreted virions and associated corneal pathology, favoring a multiplexed gene editing approach.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×